LobbyingGO2 Foundation for Lung Cancer-Fka Lca- on Behalf of Deadliest Cancers Coalition lobbying by quarter
GO2 Foundation for Lung Cancer-Fka Lca- on Behalf of Deadliest Cancers Coalition's latest lobbying report covers Q1 2026, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Medicare/Medicaid.
GO2 Foundation for Lung Cancer-Fka Lca- on Behalf of Deadliest Cancers Coalition
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $0 | 1 |
| Q1 2023 | $10K | 1 |
| Q2 2023 | $5,000 | 1 |
| Q3 2023 | $5,000 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $5,000 | 1 |
| Q2 2024 | $5,000 | 1 |
| Q3 2024 | $5,000 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Budget and appropriations$32.5K · 14 reports
- Health issues$2,500 · 2 reports
- Medicare and Medicaid$0 · 3 reports
- Medical research and clinical labs$0 · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES14 reports
- SENATE14 reports
- Office of Science & Technology Policy (OSTP)6 reports
- President of the U.S.6 reports
- Vice President of the U.S.6 reports
- Health & Human Services, Dept of (HHS)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| MGD Strategies | $35K | 14 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 08/19for Q1 | MGD Strategies | Under $5,000 |
| 05/05for Q1 | MGD Strategies | Under $5,000 |
| 02/10for Q4 2025 | MGD Strategies | Under $5,000 |
| 25/11/06for Q3 2025 | MGD Strategies | Under $5,000 |
| 25/08/20for Q2 2025 | MGD Strategies | Under $5,000 |
| 25/05/12for Q1 2025 | MGD Strategies | Under $5,000 |
| 25/05/12for Q1 2025 | MGD Strategies | Under $5,000 |
| 25/02/04for Q4 2024 | MGD Strategies | Under $5,000 |
| 24/10/29for Q3 2024 | MGD Strategies | $5,000 |
| 24/07/12for Q2 2024 | MGD Strategies | $5,000 |
| 24/05/09for Q1 2024 | MGD Strategies | $5,000 |
| 24/02/08for Q4 2023 | MGD Strategies | Under $5,000 |
| 23/11/17for Q3 2023 | MGD Strategies | $5,000 |
| 23/08/13for Q2 2023 | MGD Strategies | $5,000 |
| 23/05/03for Q1 2023 | MGD Strategies | $10K |
| 23/02/09for Q4 2022 | MGD Strategies | Under $5,000 |